Regeneron’s Pasatru receives FDA clearance for rare bone-growth disorder
The FDA approved Pasatru, a Regeneron drug targeting fibrodysplasia ossificans progressiva, an ultra-rare condition that forces abnormal bone formation.
Regeneron Pharmaceuticals secured approval for its new therapy, Pasatru, to treat fibrodysplasia ossificans progressiva (FOP). The disease causes bone to develop in soft tissues, often leaving patients wheelchair-bound by their mid-twenties and reducing life expectancy. Researchers hope the medication will preserve mobility and extend survival. Richard Keen, who led the pivotal clinical trial at London’s Royal National Orthopaedic Hospital, said the treatment nearly halts new bone growth, altering the disease’s trajectory.
Why it matters
A first-of-its-kind therapy could dramatically improve quality of life and lifespan for patients with a debilitating rare disease.
In this story
